top of page
Cardio-Oncology Mediterranean group
![LOGO_GMEDICO_FR+++.png](https://static.wixstatic.com/media/91a11f_967ffae88e954bd5b8fcf08d7a3b60b6~mv2.png/v1/crop/x_554,y_306,w_6031,h_4223/fill/w_106,h_75,al_c,q_85,usm_0.66_1.00_0.01,enc_auto/LOGO_GMEDICO_FR%2B%2B%2B.png)
Bcr-Abl inhibitors
(e.g., imatinib, dasatinib, bosutinib, nilotinib, ponatinib)
imatinib
bosutinib, dasatinib**
Clinical CV examination by the hematologist AND ECG
before cancer treatment begins
Normal
Abnormal
Monitoring by the hematolgist
Cardio-oncological evaluation*
before the cancer treatment begins
nilotinib, ponatinib
Cardio-oncological evaluation*AND PAD screening by ankle brachial index measurement and Doppler of carotid/lower extremity arteries
before the cancer treatment begins
Cardio-oncology evaluation* AND home blood pressure monitoring
every 3 months for 1 year, then every 6 months during
the Bcr-Abli therapy
PAD screening by ankle brachial index measurement and Doppler of carotid/lower extremity arteries
every 6 months if high or very high CV risk and yearly if intermediate risk
* A cardio-oncological evaluation will systematically include at least one visit with blood pressure, blood glucose, lipid profile, GFR calculation, ECG and trans-thoracic echocardiography (TTE). Measurements of global longitudinal strain and 3D LVEF (if feasible) are recommended with the same machine.
**TTE is recommended for baseline pulmonary pressure assessment.
*** Estimated by the 2022 ESC guidelines
CV=cardiovascular; PAD=peripheral artery disease; TTE=transthoracic echocardiogram
bottom of page